Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

<< Previous

Bullboard Posts

Next >>

Post by ScienceFirston May 10, 2023 7:49pm

333 Views

Post# 35442056

Upcoming events

3 legitimate things can happen now, apart from ongoing Breakthrough application procedures and planned jv negociations :

1) Management is trying to leave the TMX-V in anticipation of FDA Breakthrough decision, in order to have more visibility, when decision comes and if Accelerated Approval is also into discussions

2) Management is trying to find investment firms that could lead TLT higher, once a pp a completed.

TMX-V is no more suited for our needs given the commercialization phase we have entered and the first-class data we now have.

3) Participations, like many other biotechs do, to healthcare conferences like JP Morgan Healthcare Conference. RBC Global Healthcare Conference (presented by RBC Markets), H.C. Wainwright Global Investment Conference 2023 New York, etc ... in order to enlarge our investor bases in order to prepare for our uplisting on the TMX or NASDAQ.

All normal steps for biotechs that are maturing.